account_id none on file
legal_name Marker Therapeutics, Inc.
ticker MRKR
cik 1094038
domain markertherapeutics.com
linkedin_company_url https://www.linkedin.com/company/marker-therapeutics
entry_point_account_id none on file
name Marker Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Houston, TX, United States
sector index/company/sector/health-care/
calls 0 filings 1 executives 5 family 0
why_nownone on file
callsnone on file
filings
The increase of $0.1 million in 2026 was primarily attributable to increases in headcount-related expenses. Other Income Grant Income In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (“CPRIT”), to support the clinical investigation of MT-401 as an Off-the-Shelf (“OTS”) product in patients wi
filing / Aug 14, 2026 / receipt
executives
| Anthony Kim | Chief Financial Officer | - | receipt |
| Eliot M. Lurier | Interim Chief Financial Officer | - | receipt |
| Juan Vera | President and Chief Executive Officer | - | receipt |
| Konstantine Sarafis | Chief Operating Officer | - | receipt |
| Steve Elms | director | - | receipt |
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changes
| 2023-07-03 | Interim Chief Financial Officer, appointed | sec_8k |
| 2023-05-01 | President and Chief Executive Officer, appointed | sec_8k |
| 2019-08-06 | director, appointed | sec_8k |
| 2018-12-03 | Chief Financial Officer, appointed | sec_8k |
| 2017-04-28 | President, departed | sec_8k |
| 2013-02-25 | director, departed | sec_8k |
| 2012-08-30 | director, departed | sec_8k |
| 2004-09-01 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug marker-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$